Bouhour, S., Plantefève, R., Gillet, V., Abolghasemi, A., Bouchouirab, F. Z., Baccarelli, A. A., Takser, L., & Çaku, A. (2024). Establishing non-fasting reference values for plasma lipids levels based on age, sex, and puberty stage in a French-Canadian pediatric population. Lipids in Health and Disease, 23(1). https://doi.org/10.1186/s12944-024-02040-0

Ginsberg, H. N., & Goldberg, I. J. (2023). Broadening the Scope of Dyslipidemia Therapy by Targeting APOC3 (Apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like Protein 3). Arteriosclerosis, Thrombosis, and Vascular Biology, 43(3), 388–398. https://doi.org/10.1161/atvbaha.122.317966

Kim, K., Ginsberg, H. N., & Choi, S. H. (2022). New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins. Diabetes & Metabolism Journal, 46(4), 517–532. https://doi.org/10.4093/dmj.2022.0198

Tokgozoglu, L., Orringer, C., Ginsberg, H. N., & Catapano, A. L. (2022). The year in cardiovascular medicine 2021: dyslipidaemia. European Heart Journal, 43(8), 807–817. https://doi.org/10.1093/eurheartj/ehab875

Tall, A. R., Thomas, D. G., Gonzalez-Cabodevilla, A. G., & Goldberg, I. J. (2022). Addressing dyslipidemic risk beyond LDL-cholesterol. Journal of Clinical Investigation, 132(1). https://doi.org/10.1172/jci148559